

Approved



South Sudan
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		1,674,070	2,010,000	3,684,070	2,154,710	5,838,780
DOD		1,053,087		1,053,087	299,974	1,353,061
HHS/CDC	200,000	12,808,159		13,008,159	0	13,008,159
Total	200,000	15,535,316	2,010,000	17,745,316	2,454,684	20,200,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				Total
	DOD	HHS/CDC	State/SGAC	USAID	
CIRC	205,905	0		0	205,905
HBHC	0	7,838		401,462	409,300
HKID	0	0		495,867	495,867
HLAB	0	799,793		0	799,793
HMBL	0	411,484		0	411,484
HMIN	0	0		0	0
HTXD	0	69,304		214,638	283,942
HTXS	422,871	4,949,846	0	764,349	6,137,066
HVAB	0	0		0	0
HVCT	154,382	2,200,802		643,577	2,998,761
HVMS	0	1,043,253		0	1,043,253
HVOP	161,881	105,090		585,390	852,361
HVSI	0	1,572,137		39,485	1,611,622
HVTB	6,712	204,120		32,856	243,688
IDUP	0	0		0	0

Approved



MTCT	14,077	855,435		339,846	1,209,358
OHSS	0	42,431		39,485	81,916
PDCS	40,273	373,415		85,318	499,006
PDTX	46,986	373,211		41,797	461,994
	1,053,087	13,008,159	0	3,684,070	17,745,316



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	409,300
HKID	495,867
HVTB	229,545
PDCS	499,006
Total Technical Area Planned Funding:	1,633,718

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	672,500
HVSI	1,463,114
OHSS	39,485
Total Technical Area Planned Funding:	2,175,099

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	205,905
HMBL	390,268
HMIN	0
HVAB	0
HVCT	2,956,330
HVOP	852,361
IDUP	0
MTCT	1,188,142
Total Technical Area Planned Funding:	5,593,006

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	214,638
HTXS	5,723,435
PDTX	405,420
Total Technical Area Planned Funding:	6,343,493

Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	96 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,003
	Number of new ANC and L&D clients	45,023
	By Age (Denominator): 10-14	94
	By Age (Denominator): <15-19	4,120
	By Age (Denominator): 20-24	7,971
	By Number of known positives: 10-14	2
	By Number of known positives: 15-19	99
	By Number of known positives: 20-24	203
	By Number of new positives: 15-19	62
	By Number of new positives: 20-24	224
	By Number of new negative: 10-14	410
	By Number of new negative: 15-19	3,952
	By Number of new negative: 20-24	7,259
	By Age (Numerator): Unknown Age	8
	By Age (Numerator): 10-14	398
	By Age (Numerator): 15-19	4,102
By Age (Numerator): 20-24	7,680	



PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	16,773
PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	13,557
PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,508
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	775
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	19,555
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	441
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	778
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	8,515
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	145
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	99
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	147
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	6
PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	20,675



	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,641
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	187
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	22
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,735
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,003
	New on ART	1,406
	Already on ART at beginning of current pregnancy	1,329
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,031
	By Age: 15-19	258
	By Age: 20-24	284
	By Age: 25-29	284
	By circumcision technique: Surgical VMMC	1,031
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	69



	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	68
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	68
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,200
	Age/sex: 15-19 Male	67
	Age/sex: 20-24 Male	408
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	992
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,451
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,536
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	746
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or	5,650



	meet the minimum standards required	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	40
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,610
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	98 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,797
	Total number of registered new and relapsed TB cases, during the reporting period.	6,910
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	426
	Aggregated Age/Sex: Male 15+	4,309



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	348
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,710
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	436
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,334
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	364
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,716
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	317,973
	Service Delivery Point (Facility)	705



	Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility)	42
	Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility)	612
	Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility)	47
	Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility)	3,175
	Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility)	199
	Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility)	1,245
	Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility)	97
	Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility)	7,474
	Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility)	524
	Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility)	3,014
	Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility)	209
	Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility)	570
	Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility)	23
	Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility)	416
	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	33
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	387
	Inpatient: <1, Negative	
	Service Delivery Point (Facility)	12



	Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,777
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	70
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	55
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	1
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	35
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	924
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	32
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	852
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	32
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,405
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	105



	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,382
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	76
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	197
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	4
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	284
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	10
	Service Delivery Point (Community) Mobile Testing: <1, Negative	2
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	45
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	2
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	731
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	12
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	594
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	13
	Service Delivery Point (Facility) Other PITC: 15-19, Female,	3,444



	Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	163
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,528
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	99
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,518
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	264
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,284
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	209
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	984
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	64
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	974
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	53
	Service Delivery Point (Facility)Other PITC: <1, Negative	331
	Service Delivery Point (Facility) Other PITC: <1, Positive	9
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,036
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	31



	Service Delivery Point (Facility) Pediatric : <5 Negative	2,514
	Service Delivery Point (Facility) Pediatric : <5 Positive	134
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	87
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	12
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	118
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	18
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	135
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	19
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	229
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	38
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	202
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	31
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	551
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	89
	Service Delivery Point (Facility) TB: 50+, Female, Negative	161
	Service Delivery Point (Facility) TB: 50+, Female, Positive	27
	Service Delivery Point (Facility) TB: 50+, Male, Negative	377



Service Delivery Point (Facility) TB: 50+, Male, Positive	66
Service Delivery Point (Facility) TB: <1, Negative	26
Service Delivery Point (Facility) TB: <1, Positive	3
Service Delivery Point (Facility) TB: 1-9, Negative	536
Service Delivery Point (Facility) TB: 1-9, Positive	90
Service Delivery Point (Facility) VMC: 15-19, Negative	251
Service Delivery Point (Facility) VMC: 15-19, Positive	6
Service Delivery Point (Facility) VMC: 20-24, Negative	276
Service Delivery Point (Facility) VMC: 20-24, Positive	8
Service Delivery Point (Facility) Index: 10-14, Female, Negative	297
Service Delivery Point (Facility) Index: 10-14, Female, Positive	39
Service Delivery Point (Facility) Index: 10-14, Male, Negative	175
Service Delivery Point (Facility) Index: 10-14, Male, Positive	29
Service Delivery Point (Facility) Index: 15-19, Female, Negative	439
Service Delivery Point (Facility) Index: 15-19, Female, Positive	65
Service Delivery Point (Facility) Index: 15-19, Male, Negative	265
Service Delivery Point (Facility) Index: 15-19, Male, Positive	49



Service Delivery Point (Facility) Index: 20-24, Female, Negative	818
Service Delivery Point (Facility) Index: 20-24, Female, Positive	97
Service Delivery Point (Facility) Index: 20-24, Male, Negative	562
Service Delivery Point (Facility) Index: 20-24, Male, Positive	77
Service Delivery Point (Facility) Index: 50+, Female, Negative	83
Service Delivery Point (Facility) Index: 50+, Female, Positive	4
Service Delivery Point (Facility) Index: 50+, Male, Negative	132
Service Delivery Point (Facility) Index: 50+, Male, Positive	2
Service Delivery Point (Facility) Index: <1, Negative	25
Service Delivery Point (Facility) Index: <1, Positive	3
Service Delivery Point (Facility) Index: 1-9, Negative	285
Service Delivery Point (Facility) Index: 1-9, Positive	29
By Key Population: FSW, Negative	4,736
By Key Population: FSW, Positive	291
By Key Population: MSM, Negative	40
By Key Population: MSM, Positive	2
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	35
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	3
Service Delivery Point (Facility) ANC: 10-14, Negative	3,792



Service Delivery Point (Facility) ANC: 10-14, Positive	81
Service Delivery Point (Facility) ANC: 15-19, Negative	3,906
Service Delivery Point (Facility) ANC: 15-19, Positive	86
Service Delivery Point (Facility) ANC: 1-9, Negative	1
Service Delivery Point (Facility) ANC: 20-24, Negative	7,244
Service Delivery Point (Facility) ANC: 20-24, Positive	161
Service Delivery Point (Facility) ANC: 50+, Negative	19
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,944
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	115
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,506
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	93
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,443
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	474
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	5,056
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	196
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	11,322
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	733



Service Delivery Point (Facility) VCT: 20-24, Male, Negative	11,464
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	518
Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,020
Service Delivery Point (Facility) VCT: 50+, Female, Positive	212
Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,608
Service Delivery Point (Facility) VCT: 50+, Male, Positive	215
Service Delivery Point (Facility) VCT: <1, Negative	256
Service Delivery Point (Facility) VCT: <1, Positive	18
Service Delivery Point (Facility) VCT: 1-9, Negative	3,970
Service Delivery Point (Facility) VCT: 1-9, Positive	258
HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Negative	1
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	1
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	1
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	2
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	7
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	34
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	7



HTS_TST_N_DSD_EW_Age_Sex_	35
Result 25-29, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	1
Result 25-29, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	2
Result 25-29, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	1
Result 25-29, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	18
Result 30-34, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	3
Result 30-34, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	43
Result 30-34, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	7
Result 30-34, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	13
Result 35-39, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	2
Result 35-39, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	8
Result 35-39, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	1
Result 35-39, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	5
Result 40-49, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	1
Result 40-49, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	8
Result 40-49, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	1
Result 40-49, Male, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	1,211
Result 25-29, Female, Negative	



HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	151
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	673
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	112
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	788
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	95
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	462
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	55
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	312
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	22
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	156
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	14
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	22
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	3
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	22
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	11,926
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	729



HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	7,907
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Positive	501
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	10,397
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	684
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	4,890
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	347
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	1,192
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	111
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	1,076
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	48
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	227
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	3
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	172
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	1
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	2,783
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	136



HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,819
HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	77
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,347
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	69
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,322
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	100
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	873
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	51
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	946
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	43
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	183
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	5
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	255
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	12



HTS_TST_N_DSD_MN_Age_Sex_	848
Result <5, Unknown Sex, Negative	
HTS_TST_N_DSD_MN_Age_Sex_	46
Result <5, Unknown Sex, Positive	
HTS_TST_N_DSD_NdxMod_Age_	73
Sex_Result 25-29, Male, Negative	
HTS_TST_N_DSD_NdxMod_Age_	6
Sex_Result 25-29, Male, Positive	
HTS_TST_N_DSD_NdxMod_Age_	106
Sex_Result 30-34, Male, Negative	
HTS_TST_N_DSD_NdxMod_Age_	9
Sex_Result 30-34, Male, Positive	
HTS_TST_N_DSD_NdxMod_Age_	144
Sex_Result 35-39, Male, Negative	
HTS_TST_N_DSD_NdxMod_Age_	11
Sex_Result 35-39, Male, Positive	
HTS_TST_N_DSD_OtPITC_Age_	6,006
Sex_Result 25-29, Female,	
Negative	
HTS_TST_N_DSD_OtPITC_Age_	332
Sex_Result 25-29, Female,	
Positive	
HTS_TST_N_DSD_OtPITC_Age_	5,846
Sex_Result 25-29, Male, Negative	
HTS_TST_N_DSD_OtPITC_Age_	340
Sex_Result 25-29, Male, Positive	
HTS_TST_N_DSD_OtPITC_Age_	6,484
Sex_Result 30-34, Female,	
Negative	
HTS_TST_N_DSD_OtPITC_Age_	322
Sex_Result 30-34, Female,	
Positive	
HTS_TST_N_DSD_OtPITC_Age_	3,018
Sex_Result 30-34, Male, Negative	



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	144
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	43
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	12,166
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	269
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	12,097
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	267
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	989
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	19
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	45
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1,147
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	200
HTS_TST_N_DSD_TBC_Age_Sex	1,139



	_Result 30-34, Female, Negative	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Positive	187
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	969
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	176
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	36
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	3
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	10
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	3
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	2
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	1
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	3
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	1
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	22,521
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	1,514
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	16,165
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	1,279
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	18,007
	HTS_TST_N_DSD_VCT_Age_Sex	1,071



	_Result 30-34, Female, Positive	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	4,815
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	598
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	1,614
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	139
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	879
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	151
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	693
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	83
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	906
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	130
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Negative	275
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Positive	9
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Negative	67
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Positive	2
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Negative	68
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Positive	1
	HTS_TST_N_DSD_VMMC_Age_S	67



	ex_Result 40-49, Male, Negative	
	HTS_TST_N_DSD_VMMC_Age_Sex ex_Result 40-49, Male, Positive	1
GEND_GBV_DSD	Number of people receiving post-GBV care	921
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	796
	By type of service: Sexual Violence (Post-Rape Care)	124
	By PEP service provision (related to sexual violence services provided)	122
	15-19, Female, Physical and/or Emotional Violence	30
	15-19, Female, Sexual Violence (Post-Rape Care)	12
	20-24, Female, Physical and/or Emotional Violence	366
	20-24, Female, Sexual Violence (Post-Rape Care)	108
	50+, Female, Physical and/or Emotional Violence	2
	50+, Female, Sexual Violence (Post-Rape Care)	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	197
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	25
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	148



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	10
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	24
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,617
	Age/Sex: 10-14 Male	344
	Age/Sex: 15-17 Male	226
	By: Age/sex: Male 25+	106
	Age/Sex: 10-14 Female	301
	Age/Sex: 15-17 Female	210
	By: Age/sex: 18-24 Female	19
	By: Age/sex: 25+ Female	405
	Sum of Age/Sex disaggregates	1,081
	Age/Sex: <1	55
	Age/Sex: 1-9	951
	Program Completion: Active	1,884
	Program Completion: Graduation	733
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	80 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	2,087
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	2,617



	HIV/AIDS	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,044
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	635
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	391



	ART during TB treatment during the reporting period)	
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	24 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,109
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,949
	By Age/Sex (Denominator): <15, Female	70
	By Age/Sex (Denominator): <15, Male	1,055
	By Age/Sex (Denominator): 15+, Female	2,109
	By Age/Sex (Denominator): 15+, Male	3,795
	By Age/Sex (Numerator): <15, Female	21
	By Age/Sex (Numerator): <15, Male	316
	By Age/Sex (Numerator): 15+, Female	633
	By Age/Sex (Numerator): 15+, Male	1,139



	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	70
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,109
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	1,055
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	3,796
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	21
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	633
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	316
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	1,139
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	1 %
	Number of ART patients who were started on TB treatment during the reporting period.	319
	Number of ART patients who were	25,767



	screened for TB at least once during the reporting period	
	Numerator: By Aggregated Age/Sex: <15, Female	9
	Numerator: By Aggregated Age/Sex: <15, Male	9
	Numerator: By Aggregated Age/Sex: 15+, Female	124
	Numerator: By Aggregated Age/Sex: 15+, Male	177
	Denominator: By Aggregated Age/Sex: <15, Female	542
	Denominator: By Aggregated Age/Sex: <15, Male	536
	Denominator: By Aggregated Age/Sex:15+, Female	12,412
	Denominator: By Aggregated Age/Sex:15+, Male	12,278
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	23,847
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	15,715
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	7,831
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	9,772
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive,	8,060



	Positive	
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,551
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,182
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,753
	By infants who received a virologic test within 2 months of birth	1,629
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,124
	Sum of Infant Age disaggregates	2,753
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	41,840
	Age/Sex: 15-19 Male	351
	Age/Sex: 15-19 Female	867
	Age/Sex: <1	238
	Age/Sex: <1-9	899
	Age/Sex: 10-14 Male	376
	Age/Sex: 10-14 Female	524
	Age/Sex: 20-24 Male	1,279
	Age/Sex: 50+ Male	1,225
	Age/Sex: 20-24 Female	2,824
	Age/Sex: 50+ Female	728
TX_CURR_N_DSD_Age_Sex_HIV	9,815	



	Status 25-29, Female, Positive	
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	6,476
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	6,038
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	3,952
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	2,085
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	1,366
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	1,583
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	1,213
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,553
	By Age/Sex: <1	116
	By Age/Sex: 1-9	165
	By Age/Sex: 10-14 Male	221
	By Age/Sex: 15-19 Male	139
	By Age/Sex: 20-24 Male	1,001
	By Age/Sex: 50+ Male	335
	By Age/Sex: 10-14 Female	514
	By Age/Sex: 15-19 Female	205
	By Age/Sex: 20-24 Female	1,362
	By Age/Sex: 50+ Female	390
	Pregnancy status	2,089
	Breastfeeding status	136
	MSM	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIV tatus 25-29, Female, Positive	3,082



	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	2,851
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	1,763
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	1,435
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	1,774
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,006
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	568
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	626
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	27,911
	Denominator: Indication: Routine	27,911
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	279
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,099
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	557
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,977



TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	85 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,985
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,769
	Numerator by Status: Pregnant	407
	Numerator by Status: Breastfeeding	390
	Denominator by Status: Pregnant	526
	Denominator by Status: Breastfeeding	183
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,570
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	305



	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,833
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	289
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,042
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	335
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	6,868

Approved



	those lost to follow-up)	
--	--------------------------	--



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
14418	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17700	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,260,000
17701	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,303,581
17708	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,620,201



17713	FHI 360	NGO	U.S. Agency for International Development		
17714	JHPIEGO	University	U.S. Agency for International Development	GHP-USAID	1,444,074
17805	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	1,053,087
17832	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,146,335
18133	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	495,867
18236	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	445,752
18397	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,678,042
70312	[Placeholder]	TBD	U.S. Department of Defense		
70313	[Placeholder]	TBD	U.S. Department of Defense		
70314	[Placeholder]	TBD	U.S. Department of Defense		
70315	[Placeholder]	TBD	U.S. Department		



			of Health and Human Services/Centers for Disease Control and Prevention		
70316	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70317	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70318	TBD	TBD	Redacted	Redacted	Redacted
70319	[Placeholder]	TBD	U.S. Agency for International Development		
70320	[Placeholder]	TBD	U.S. Agency for International Development		
70515	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 14418	Mechanism Name: Intrahealth SI-OHSS (ENDED March 31/2017)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14418	
Mechanism Name:	Intrahealth SI-OHSS (ENDED March 31/2017)	
Prime Partner Name:	IntraHealth International, Inc	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17700	Mechanism Name: AMREF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,260,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,260,000	
Funding Source	Funding Amount
GHP-State	1,260,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17700 Mechanism Name: AMREF Prime Partner Name: African Medical and Research Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	21,875
Strategic Area	Budget Code	Planned Amount
Care	PDCS	140,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	672,500
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	65,625
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	210,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17701	Mechanism Name: International Center for AIDS Care and Treatment Programs, Columbia University
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,303,581	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,303,581	
Funding Source	Funding Amount
GHP-State	3,303,581

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17701	
Mechanism Name:	International Center for AIDS Care and Treatment Programs, Columbia University	
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	7,838
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	94,064
Strategic Area	Budget Code	Planned Amount
Care	PDCS	39,192
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	240,268
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	522,573



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	105,090
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	345,358
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,766,297
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	182,901

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	380
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,819
PMTCT_ART_DSD	New on ART	304
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	76
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,819



PMTCT_STAT_DSD	Number of new ANC and L&D clients	9,019
PMTCT_STAT_DSD	By Age (Denominator): 10-14	5
PMTCT_STAT_DSD	By Age (Denominator): <15-19	844
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,656
PMTCT_STAT_DSD	By Number of known positives: 15-19	6
PMTCT_STAT_DSD	By Number of known positives: 20-24	16
PMTCT_STAT_DSD	By Number of new positives: 15-19	14
PMTCT_STAT_DSD	By Number of new positives: 20-24	61
PMTCT_STAT_DSD	By Number of new negative: 10-14	86
PMTCT_STAT_DSD	By Number of new negative: 15-19	831
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,517
PMTCT_STAT_DSD	By Age (Numerator): 10-14	86
PMTCT_STAT_DSD	By Age (Numerator): 15-19	853
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,592
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,505
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,767
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	242
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	57
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,184
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	149
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	57
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,769
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	33
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	4
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,390
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,857
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	12
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	85,934
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	340
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	292
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,088
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	817
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,635
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	354
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,813
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	380



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	194
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,905
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,004
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	754
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,264
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,550
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	91



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	849
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	141



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	393
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	292
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	396
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	293



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	844
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	830
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,534
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	371
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	13



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	327
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,304
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,014
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	272
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	364



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	212
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	7,650
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	487
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	4,873
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	349
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	6,240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	438



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	3,123
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	236
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	850
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	297
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,805
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,052
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,292
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	961
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,526

HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,526
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	814
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	811
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	687
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,801
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,455
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,271



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	430
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	415
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	14
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,443
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,538
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,577
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	110
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	606
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	158
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,638
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	118



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	622
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	406
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	237
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	151
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	412
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	247
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	165
PMTCT_EID_DSD	Sum of Infant Age disaggregates	412
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,458
TX_CURR_DSD	Age/Sex: 15-19 Male	32
TX_CURR_DSD	Age/Sex: 15-19 Female	257
TX_CURR_DSD	Sum of age/sex disaggregates	289



TX_CURR_DSD	Age/Sex: <1	118
TX_CURR_DSD	Age/Sex: <1-9	385
TX_CURR_DSD	Age/Sex: 10-14 Male	48
TX_CURR_DSD	Age/Sex: 10-14 Female	113
TX_CURR_DSD	Age/Sex: 20-24 Male	298
TX_CURR_DSD	Age/Sex: 50+ Male	492
TX_CURR_DSD	Age/Sex: 20-24 Female	917
TX_CURR_DSD	Age/Sex: 50+ Female	236
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,226
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,161
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,916
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,277
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	639
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	384
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	575
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	384
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,673
TX_NEW_DSD	By Age/Sex: <1	20
TX_NEW_DSD	By Age/Sex: 1-9	30
TX_NEW_DSD	By Age/Sex: 10-14 Male	14
TX_NEW_DSD	By Age/Sex: 15-19 Male	29
TX_NEW_DSD	By Age/Sex: 20-24 Male	274
TX_NEW_DSD	By Age/Sex: 50+ Male	137
TX_NEW_DSD	By Age/Sex: 10-14 Female	148



TX_NEW_DSD	By Age/Sex: 15-19 Female	44
TX_NEW_DSD	By Age/Sex: 20-24 Female	361
TX_NEW_DSD	By Age/Sex: 50+ Female	130
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,137
TX_NEW_DSD	Pregnancy status	536
TX_NEW_DSD	Breastfeeding status	41
TX_NEW_DSD	MSM	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	930
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	795
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	455
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	313
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	499
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	239
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	107
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,343
TX_PVLS_DSD	Denominator: Indication: Routine	11,343
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	113
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,331
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	227
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	5,671



	Female Routine	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,939
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,280
TX_RET_DSD	Numerator by Status: Pregnant	118
TX_RET_DSD	Numerator by Status: Breastfeeding	148
TX_RET_DSD	Denominator by Status: Pregnant	138
TX_RET_DSD	Denominator by Status: Breastfeeding	58
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	982
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	102
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,751
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	93
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,133
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	104



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,911
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	936
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,039
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	31
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	468
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	936
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,684
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	9
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	140
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	281
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	506
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	31
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	936
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	468

TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,685
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	9
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	281
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	140
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	506
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	301
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,163
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	9
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	9
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	114
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	169
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	169
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	179
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,977
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	4,837
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,163
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	4,699
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,464
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6,405
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	926



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,602
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	230

Implementing Mechanism Details

Mechanism ID: 17708	Mechanism Name: IHI - prevention, care and treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,620,201	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,620,201	
Funding Source	Funding Amount
GHP-State	1,620,201

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17708	
Mechanism Name:	IHI - prevention, care and treatment	
Prime Partner Name:	IntraHealth International, Inc	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	38,632
Strategic Area	Budget Code	Planned Amount
Care	PDCS	70,303
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	575,770



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	112,813
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	777,461
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	45,222

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	135
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,262
PMTCT_ART_DSD	New on ART	116
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	19
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,262



PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,471
PMTCT_STAT_DSD	By Age (Denominator): <15-19	407
PMTCT_STAT_DSD	By Age (Denominator): 20-24	803
PMTCT_STAT_DSD	By Number of known positives: 15-19	2
PMTCT_STAT_DSD	By Number of known positives: 20-24	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	2
PMTCT_STAT_DSD	By Number of new positives: 20-24	8
PMTCT_STAT_DSD	By Number of new negative: 10-14	37
PMTCT_STAT_DSD	By Number of new negative: 15-19	399
PMTCT_STAT_DSD	By Number of new negative: 20-24	690
PMTCT_STAT_DSD	By Age (Numerator): 10-14	37
PMTCT_STAT_DSD	By Age (Numerator): 15-19	404
PMTCT_STAT_DSD	By Age (Numerator): 20-24	701
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,699
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,340
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	222
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,916
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	996
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,004



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,022
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	11
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	58,804
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	618
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,799
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	767
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	134



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	490
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	13



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,143
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	8



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	356
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	365
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	692
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	194
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	248
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	439
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,092
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,296
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,566
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	954
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	15



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,173
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	237
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,048
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	177



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,280
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3,112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,286
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	241
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	226
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	866



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	765
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	965
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	565
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,233
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,298
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	222
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	6,064
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	226
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,455
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	5,564
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	181
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,245
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	57

	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	247
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	256
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	4
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	772
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	772
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	439
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	250
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	47

	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	428
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	247
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	100
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	122
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	73
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	49
PMTCT_EID_DSD	Sum of Infant Age disaggregates	122
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,517
TX_CURR_DSD	Age/Sex: 15-19 Male	13
TX_CURR_DSD	Age/Sex: 15-19 Female	110
TX_CURR_DSD	Sum of age/sex disaggregates	123



TX_CURR_DSD	Age/Sex: <1	32
TX_CURR_DSD	Age/Sex: <1-9	60
TX_CURR_DSD	Age/Sex: 10-14 Male	86
TX_CURR_DSD	Age/Sex: 10-14 Female	53
TX_CURR_DSD	Age/Sex: 20-24 Male	119
TX_CURR_DSD	Age/Sex: 50+ Male	196
TX_CURR_DSD	Age/Sex: 20-24 Female	375
TX_CURR_DSD	Age/Sex: 50+ Female	96
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,462
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	974
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	792
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	521
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	263
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	159
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	123
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	82
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,923
TX_NEW_DSD	By Age/Sex: <1	31
TX_NEW_DSD	By Age/Sex: 1-9	35
TX_NEW_DSD	By Age/Sex: 10-14 Male	67
TX_NEW_DSD	By Age/Sex: 15-19 Male	35
TX_NEW_DSD	By Age/Sex: 20-24 Male	161
TX_NEW_DSD	By Age/Sex: 50+ Male	42
TX_NEW_DSD	By Age/Sex: 10-14 Female	57



TX_NEW_DSD	By Age/Sex: 15-19 Female	42
TX_NEW_DSD	By Age/Sex: 20-24 Female	214
TX_NEW_DSD	By Age/Sex: 50+ Female	48
TX_NEW_DSD	Sum of Age/Sex disaggregates	666
TX_NEW_DSD	Pregnancy status	360
TX_NEW_DSD	Breastfeeding status	22
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	535
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	523
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	271
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	232
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	325
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	138
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	87
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	80
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,492
TX_PVLS_DSD	Denominator: Indication: Routine	3,492
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	35
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,642
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	70
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,746



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	930
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,034
TX_RET_DSD	Numerator by Status: Pregnant	37
TX_RET_DSD	Numerator by Status: Breastfeeding	37
TX_RET_DSD	Denominator by Status: Pregnant	44
TX_RET_DSD	Denominator by Status: Breastfeeding	19
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	329
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	565
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	362
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	22



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	629
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,769
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	72
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	73
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,887
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,739
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,769
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,217
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,552
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	377
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,885
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	754
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	754

Implementing Mechanism Details

Mechanism ID: 17713	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17713		
Mechanism Name: Linkages		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	960
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	960
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,667
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	296
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	16



	20-24, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	222
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	6
HTC_TST_DSD	By Key Population: FSW, Negative	1,473
HTC_TST_DSD	By Key Population: FSW, Positive	83
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	296
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39,	30



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
GEND_GBV_DSD	Number of people receiving post-GBV care	88
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	82
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	6
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	33
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	23
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	10



Implementing Mechanism Details

Mechanism ID: 17714	Mechanism Name: SPPHC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,444,074	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 239,270	
Total All Funding Sources and Applied Pipeline Amount: 1,683,344	
Funding Source	Funding Amount
GHP-USAID	1,444,074

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	30,000
---	--------

Budget Code Information

Mechanism ID: 17714 Mechanism Name: SPPHC Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	53,323
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	32,856
Strategic Area	Budget Code	Planned Amount
Care	PDCS	85,318
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	319,938
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	37,761
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	339,846
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	533,235
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	41,797

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	375
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,017
PMTCT_ART_DSD	New on ART	230
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	145
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,017
PMTCT_STAT_DSD	Number of new ANC and L&D clients	10,579
PMTCT_STAT_DSD	By Age (Denominator): 10-14	14
PMTCT_STAT_DSD	By Age (Denominator): <15-19	963
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,894
PMTCT_STAT_DSD	By Number of known positives: 15-19	8



PMTCT_STAT_DSD	By Number of known positives: 20-24	16
PMTCT_STAT_DSD	By Number of new positives: 15-19	25
PMTCT_STAT_DSD	By Number of new positives: 20-24	93
PMTCT_STAT_DSD	By Number of new negative: 10-14	95
PMTCT_STAT_DSD	By Number of new negative: 15-19	950
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,735
PMTCT_STAT_DSD	By Age (Numerator): 10-14	95
PMTCT_STAT_DSD	By Age (Numerator): 15-19	982
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,846
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,017
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,163
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	528
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	65
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,818
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	65
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,022
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,002
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,084
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	35,685
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	2



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	753
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	165



	20-24, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	157
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	157
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	43
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	555
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	359
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	883
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	39



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	359
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male,	38



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	962
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	950
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,752
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	68



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	675
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,120
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	973
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	364
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	564
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	59
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	41

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	802
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	905
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	534
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,066
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	6

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	217
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	943
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	825
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	636
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	366
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,886
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,886
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	70



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	192
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,141
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	217
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,606
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,605
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	217
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	409
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	26



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	26
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,380
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,398
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	224
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,149
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	191
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	816
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	226
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,158
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	193
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	820
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	425
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	261



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	164
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	379
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	227
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	152
PMTCT_EID_DSD	Sum of Infant Age disaggregates	379
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,678
TX_CURR_DSD	Age/Sex: 15-19 Male	72
TX_CURR_DSD	Age/Sex: 15-19 Female	109
TX_CURR_DSD	Sum of age/sex disaggregates	181
TX_CURR_DSD	Age/Sex: <1-9	139
TX_CURR_DSD	Age/Sex: 10-14 Male	10
TX_CURR_DSD	Age/Sex: 10-14 Female	11
TX_CURR_DSD	Age/Sex: 20-24 Male	152
TX_CURR_DSD	Age/Sex: 50+ Male	214
TX_CURR_DSD	Age/Sex: 20-24 Female	385
TX_CURR_DSD	Age/Sex: 50+ Female	102
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,348
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	906
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	828
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	560



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	275
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	167
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	239
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	161
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,174
TX_NEW_DSD	By Age/Sex: <1	7
TX_NEW_DSD	By Age/Sex: 1-9	19
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	13
TX_NEW_DSD	By Age/Sex: 20-24 Male	120
TX_NEW_DSD	By Age/Sex: 50+ Male	67
TX_NEW_DSD	By Age/Sex: 10-14 Female	65
TX_NEW_DSD	By Age/Sex: 15-19 Female	21
TX_NEW_DSD	By Age/Sex: 20-24 Female	191
TX_NEW_DSD	By Age/Sex: 50+ Female	49
TX_NEW_DSD	Sum of Age/Sex disaggregates	531
TX_NEW_DSD	Pregnancy status	177
TX_NEW_DSD	Breastfeeding status	24
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	427
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	364
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	209
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	115
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	226



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	85
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	83
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,107
TX_PVLS_DSD	Denominator: Indication: Routine	2,107
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	21
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	970
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	41
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,075
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,217
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,543
TX_RET_DSD	Numerator by Status: Pregnant	14
TX_RET_DSD	Numerator by Status: Breastfeeding	14
TX_RET_DSD	Denominator by Status: Pregnant	61
TX_RET_DSD	Denominator by Status: Breastfeeding	25
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	419



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	751
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	471
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,016
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,071
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	73
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	74
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	1,159
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	1,764
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,071



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,955
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	815
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	307
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,332
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	614
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	614

Implementing Mechanism Details

Mechanism ID: 17805		Mechanism Name: RTI Care and Treatment	
Funding Agency: DOD		Procurement Type: Grant	
Prime Partner Name: Research Triangle International			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 1,053,087		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 199,974			
Total All Funding Sources and Applied Pipeline Amount: 1,253,061			
Funding Source		Funding Amount	
GHP-State		1,053,087	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17805		
Mechanism Name: RTI Care and Treatment		
Prime Partner Name: Research Triangle International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	6,712
Strategic Area	Budget Code	Planned Amount
Care	PDCS	40,273
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	205,905
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	154,382
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	161,881
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	14,077
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	422,871
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	46,986

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	83
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	1,748



	their results)	
PMTCT_ART_DSD	New on ART	37
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	46
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,748
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,840
PMTCT_STAT_DSD	By Age (Denominator): <15-19	167
PMTCT_STAT_DSD	By Age (Denominator): 20-24	331
PMTCT_STAT_DSD	By Number of known positives: 15-19	4
PMTCT_STAT_DSD	By Number of known positives: 20-24	9
PMTCT_STAT_DSD	By Number of new positives: 15-19	3
PMTCT_STAT_DSD	By Number of new positives: 20-24	5
PMTCT_STAT_DSD	By Number of new negative: 15-19	153
PMTCT_STAT_DSD	By Number of new negative: 20-24	300
PMTCT_STAT_DSD	By Age (Numerator): 15-19	160
PMTCT_STAT_DSD	By Age (Numerator): 20-24	314
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	699
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	552
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	91
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	20
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	632
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	12
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	16
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	499
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	3



	35-39, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	664
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	86
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,031
VMMC_CIRC_DSD	By Age: 15-19	258
VMMC_CIRC_DSD	By Age: 20-24	284
VMMC_CIRC_DSD	By Age: 25-29	284
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	542
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	826
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,031
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	69
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	68
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	68
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,604
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	211



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	356
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	321
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	635
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	251



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	267
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	526
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	35



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	13



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	344
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	161
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	420

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	632
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	498
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,001



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	682
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	437
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	715
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1

TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	81
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	81
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	70
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	70
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	52
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	79
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	47
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	32
PMTCT_EID_DSD	Sum of Infant Age disaggregates	79
TX_CURR_DSD	Number of adults and children receiving antiretroviral	2,041



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	4
TX_CURR_DSD	Age/Sex: 15-19 Female	32
TX_CURR_DSD	Sum of age/sex disaggregates	36
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	34
TX_CURR_DSD	Age/Sex: 10-14 Male	6
TX_CURR_DSD	Age/Sex: 10-14 Female	9
TX_CURR_DSD	Age/Sex: 20-24 Male	52
TX_CURR_DSD	Age/Sex: 50+ Male	78
TX_CURR_DSD	Age/Sex: 20-24 Female	146
TX_CURR_DSD	Age/Sex: 50+ Female	30
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	334
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	119
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	273
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	165
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	195
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	189
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	132
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	239
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,277
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	11
TX_NEW_DSD	By Age/Sex: 10-14 Male	6



TX_NEW_DSD	By Age/Sex: 15-19 Male	21
TX_NEW_DSD	By Age/Sex: 20-24 Male	63
TX_NEW_DSD	By Age/Sex: 50+ Male	76
TX_NEW_DSD	By Age/Sex: 10-14 Female	9
TX_NEW_DSD	By Age/Sex: 15-19 Female	38
TX_NEW_DSD	By Age/Sex: 20-24 Female	77
TX_NEW_DSD	By Age/Sex: 50+ Female	54
TX_NEW_DSD	Sum of Age/Sex disaggregates	344
TX_NEW_DSD	Pregnancy status	82
TX_NEW_DSD	Breastfeeding status	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	100
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	107
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	191
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	153
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	92
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	77
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	47
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	153
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,429
TX_PVLS_DSD	Denominator: Indication: Routine	1,429
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	14
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	672



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	29
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	714
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	947
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,456
TX_RET_DSD	Numerator by Status: Pregnant	64
TX_RET_DSD	Numerator by Status: Breastfeeding	1
TX_RET_DSD	Denominator by Status: Pregnant	99
TX_RET_DSD	Denominator by Status: Breastfeeding	2
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	492
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	445
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	757



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	684
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	18
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,939
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	8
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	26
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	24
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	1,085
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	804
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	19
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	19
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	1,900
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	16
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	19

Implementing Mechanism Details

Mechanism ID: 17832	Mechanism Name: CMMB - Prevention, Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,146,335	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,146,335	
Funding Source	Funding Amount
GHP-State	2,146,335

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17832	
Mechanism Name:	CMMB - Prevention, Care and Treatment	
Prime Partner Name:	Catholic Medical Mission Board	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	35,406
Strategic Area	Budget Code	Planned Amount
Care	PDCS	123,920
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	743,520



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	376,048
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	778,927
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	88,514

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,762
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,157
PMTCT_ART_DSD	New on ART	719
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,043
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,157



PMTCT_STAT_DSD	Number of new ANC and L&D clients	19,114
PMTCT_STAT_DSD	By Age (Denominator): 10-14	75
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,739
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,287
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	79
PMTCT_STAT_DSD	By Number of known positives: 20-24	158
PMTCT_STAT_DSD	By Number of new positives: 15-19	18
PMTCT_STAT_DSD	By Number of new positives: 20-24	57
PMTCT_STAT_DSD	By Number of new negative: 10-14	192
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,619
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,017
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	8
PMTCT_STAT_DSD	By Age (Numerator): 10-14	180
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,703
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,227
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	6,853
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	5,735
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,425
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	616
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	8,005
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	92
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	623
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,229
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	94
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	80



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,154
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	22
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	115,702
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	395
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	988
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	420
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female,	42



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	156
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	415
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,792
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,092
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	31



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,859
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	557
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	560
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	319
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,782
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	517
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male,	2



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	47



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	215
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	1,630
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,608
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,965
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,424
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,935
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	61



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	6,287
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	328
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,695
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,431
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	508
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,385
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,411
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,486
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,437
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	231



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,142
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	702
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	973
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	451
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	34



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	196
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,392
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,204
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,591
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,126



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,889
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,889
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	12,066
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	899
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	7,764



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	676
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	9,431
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	602
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,730
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	221
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	802
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	65
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	121
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	121
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total	40



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	61
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,761
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,035
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	726
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,761
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,146
TX_CURR_DSD	Age/Sex: 15-19 Male	230
TX_CURR_DSD	Age/Sex: 15-19 Female	359
TX_CURR_DSD	Sum of age/sex disaggregates	589
TX_CURR_DSD	Age/Sex: <1	84
TX_CURR_DSD	Age/Sex: <1-9	281
TX_CURR_DSD	Age/Sex: 10-14 Male	226



TX_CURR_DSD	Age/Sex: 10-14 Female	338
TX_CURR_DSD	Age/Sex: 20-24 Male	658
TX_CURR_DSD	Age/Sex: 50+ Male	245
TX_CURR_DSD	Age/Sex: 20-24 Female	1,001
TX_CURR_DSD	Age/Sex: 50+ Female	264
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,445
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,316
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,229
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,429
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	713
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	467
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	514
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	347
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,506
TX_NEW_DSD	By Age/Sex: <1	56
TX_NEW_DSD	By Age/Sex: 1-9	70
TX_NEW_DSD	By Age/Sex: 10-14 Male	129
TX_NEW_DSD	By Age/Sex: 15-19 Male	41
TX_NEW_DSD	By Age/Sex: 20-24 Male	383
TX_NEW_DSD	By Age/Sex: 50+ Male	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	235
TX_NEW_DSD	By Age/Sex: 15-19 Female	60
TX_NEW_DSD	By Age/Sex: 20-24 Female	519
TX_NEW_DSD	By Age/Sex: 50+ Female	109



TX_NEW_DSD	Sum of Age/Sex disaggregates	1,489
TX_NEW_DSD	Pregnancy status	934
TX_NEW_DSD	Breastfeeding status	37
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,090
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,062
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	637
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	622
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	632
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	444
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	201
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	203
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,540
TX_PVLS_DSD	Denominator: Indication: Routine	9,540
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	96
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,484
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	190
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,771
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,952
TX_RET_DSD	Total number of adults and children who initiated ART	4,456



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	174
TX_RET_DSD	Numerator by Status: Breastfeeding	190
TX_RET_DSD	Denominator by Status: Pregnant	184
TX_RET_DSD	Denominator by Status: Breastfeeding	79
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	130
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,348
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	153
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,321
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	144
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,319
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	171
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	2,628



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,173
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,910
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	39
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	587
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,173
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,111
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	12
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	176
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	352
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	633
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	39
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,173
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	587
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,111
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already,	12



	Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	352
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	176
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	633
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	7,825
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	202
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	186
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	4,304
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	3,134
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	7,825
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	7,825
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	783
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	3,913
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,565
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,565

Implementing Mechanism Details

Mechanism ID: 18133	Mechanism Name: 4 Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
-------------------------------------	--------------------------------------

Applied Pipeline Amount: 0

Total All Funding Sources and Applied Pipeline Amount: 0

Funding Source	Funding Amount
-----------------------	-----------------------

Cross-Cutting Budget Attribution(s)

Economic Strengthening	11,600
Education	35,000
Adolescent Girls and Young Women (AGYW)	60,000

Budget Code Information

Mechanism ID: 18133		
Mechanism Name: 4 Children		
Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	495,867
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,617
OVC_SERV_DSD	Age/Sex: 10-14 Male	344
OVC_SERV_DSD	Age/Sex: 15-17 Male	226
OVC_SERV_DSD	By: Age/sex: Male 25+	106
OVC_SERV_DSD	Age/Sex: 10-14 Female	301
OVC_SERV_DSD	Age/Sex: 15-17 Female	210
OVC_SERV_DSD	By: Age/sex: 18-24 Female	19
OVC_SERV_DSD	By: Age/sex: 25+ Female	405
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,081
OVC_SERV_DSD	Age/Sex: <1	55
OVC_SERV_DSD	Age/Sex: 1-9	951
OVC_SERV_DSD	Program Completion: Active	1,884
OVC_SERV_DSD	Program Completion: Graduation	733
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	2,087
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,617

Implementing Mechanism Details



Mechanism ID: 18236	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 445,752	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 768,886	
Total All Funding Sources and Applied Pipeline Amount: 1,214,638	
Funding Source	Funding Amount
GHP-State	445,752

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18236	
Mechanism Name:	Global Health Supply Chain Program	
Prime Partner Name:	Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	214,638
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	231,114
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18397	Mechanism Name: IntraHealth SI-OHSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,678,042	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,678,042	
Funding Source	Funding Amount
GHP-State	2,678,042

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 18397 Mechanism Name: IntraHealth SI-OHSS Prime Partner Name: IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,423,629
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	250,883
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,003,530
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 70312	Mechanism Name: [Placeholder - 70312 South Sudan DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70312		
Mechanism Name: [Placeholder - 70312 South Sudan DOD]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70313	Mechanism Name: [Placeholder - 70313 South Sudan DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70313		
Mechanism Name: [Placeholder - 70313 South Sudan DOD]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70314	Mechanism Name: [Placeholder - 70314 South Sudan DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement



Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70314		
Mechanism Name: [Placeholder - 70314 South Sudan DOD]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70315	Mechanism Name: [Placeholder - 70315 South Sudan HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70315		
Mechanism Name: [Placeholder - 70315 South Sudan HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70316	Mechanism Name: [Placeholder - 70316 South Sudan HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70316		
Mechanism Name: [Placeholder - 70316 South Sudan HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70317	Mechanism Name: [Placeholder - 70317 South Sudan HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 70317 Mechanism Name: [Placeholder - 70317 South Sudan HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70318	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70319	Mechanism Name: [Placeholder - 70319 South]
----------------------------	--



	Sudan USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70319		
Mechanism Name: [Placeholder - 70319 South Sudan USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70320	Mechanism Name: [Placeholder - 70320 South Sudan USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70320 Mechanism Name: [Placeholder - 70320 South Sudan USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70515	TBD: Yes
REDACTED	

Approved





Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	28,400	28,400
ICASS		0		0	234,000	234,000
Institutional Contractors				0	14,983	14,983
Management Meetings/Professional Development		0		0	71,000	71,000
Non-ICASS Administrative Costs		0		0	76,060	76,060
Staff Program Travel		0		0	40,000	40,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	380,078	380,078
USG Staff Salaries and Benefits - Locally Recruited		0	0	0	169,527	169,527



Total	0	0	0	0	1,014,048	1,014,048
--------------	----------	----------	----------	----------	------------------	------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	20,000	20,000
Staff Program Travel				0	20,000	20,000
USG Staff Salaries and Benefits - Locally Recruited		0		0	60,000	60,000
Total	0	0	0	0	100,000	100,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		119,691		119,691	0	119,691
Computers/IT Services		30,000		30,000	0	30,000

Approved



ICASS		450,000		450,000	0	450,000
Management Meetings/Professional Development		154,000		154,000	0	154,000
Non-ICASS Administrative Costs		40,000		40,000	0	40,000
Staff Program Travel		130,000		130,000	0	130,000
USG Staff Salaries and Benefits - Internationally Recruited	200,000			200,000	0	200,000
USG Staff Salaries and Benefits - Locally Recruited		876,309		876,309	0	876,309
Total	200,000	1,800,000	0	2,000,000	0	2,000,000